PMID- 38196558 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240111 IS - 2287-8882 (Print) IS - 2287-903X (Electronic) IS - 2287-8882 (Linking) VI - 11 IP - 4 DP - 2023 Dec TI - Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer. PG - 239-246 LID - 10.1016/j.prnil.2023.10.002 [doi] AB - BACKGROUND: In recent years, site-directed therapies (SDTs) targeting progressive lesions in patients with oligometastatic prostate cancer have attracted attention. However, whether they effectively treat oligoprogressive castration-resistant prostate cancer (CRPC) remains unclear. Here, we investigated the efficacy of SDT in patients with oligoprogressive CRPC and identified prognostic factors. METHODS: We reviewed 59 patients with oligoprogressive CRPC who underwent SDT targeting prostate or metastatic lesions between April 2014 and March 2022. We evaluated the associations between several pretreatment clinical variables and treatment procedures and a >50% prostate-specific antigen (PSA) response, progression-free survival (PFS), and time to next treatment (TTNT). RESULTS: A PSA response of >50% was observed in 66% of patients. The median PFS and TTNT were 8.3 months and 9.9 months, respectively. Patients with PSA doubling time >/=6 months showed a higher >50% PSA response rate (87% vs. 45%; P < 0.001), longer PFS (median, 15.0 vs. 5.0 months; P < 0.001), and longer TTNT (median, 16.3 vs. 5.9 months; P < 0.001) than patients with PSA doubling time <6 months. In multivariate analyses, a PSA doubling time of >/=6 months independently predicted a >50% PSA response, favorable PFS, and TTNT (P = 0.037, 0.025, and 0.017, respectively). CONCLUSION: PSA doubling time of >/=6 months may be a key indicator of the favorable efficacy of SDT for oligoprogressive CRPC. CI - (c) 2023 The Asian Pacific Prostate Society. Published by Elsevier B.V. FAU - Kawai, Taketo AU - Kawai T AD - Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan. AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Taguchi, Satoru AU - Taguchi S AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Nozaki, Keina AU - Nozaki K AD - Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan. FAU - Kimura, Naoki AU - Kimura N AD - Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan. FAU - Oshina, Takahiro AU - Oshina T AD - Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan. FAU - Iwaki, Takuya AU - Iwaki T AD - Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan. FAU - Matsui, Hotaka AU - Matsui H AD - Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan. FAU - Niimi, Aya AU - Niimi A AD - Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan. FAU - Kamei, Jun AU - Kamei J AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Akiyama, Yoshiyuki AU - Akiyama Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Yamada, Yuta AU - Yamada Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Sato, Yusuke AU - Sato Y AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Yamada, Daisuke AU - Yamada D AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Kaneko, Tomoyuki AU - Kaneko T AD - Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan. FAU - Sawayanagi, Subaru AU - Sawayanagi S AD - Department of Radiology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Nakayama, Hidetsugu AU - Nakayama H AD - Department of Radiation Oncology, Center Hospital of National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan. FAU - Minamimoto, Ryogo AU - Minamimoto R AD - Department of Radiology, Division of Nuclear Medicine, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan. FAU - Yamashita, Hideomi AU - Yamashita H AD - Department of Radiology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. FAU - Miyazaki, Hideyo AU - Miyazaki H AD - Department of Urology, Center Hospital of National Center for Global Health and Medicine, Shinjyuku-ku, Tokyo, Japan. FAU - Fujimura, Tetsuya AU - Fujimura T AD - Department of Urology, Jichi Medical University, Shimotsuke-shi, Tochigi, Japan. FAU - Nakagawa, Tohru AU - Nakagawa T AD - Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan. FAU - Kume, Haruki AU - Kume H AD - Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20231021 PL - Korea (South) TA - Prostate Int JT - Prostate international JID - 101605566 PMC - PMC10772157 OTO - NOTNLM OT - Castration-resistant prostate cancer OT - Oligometastasis OT - Oligoprogression OT - PSA doubling time OT - Site-directed therapy EDAT- 2024/01/10 06:41 MHDA- 2024/01/10 06:42 PMCR- 2023/10/21 CRDT- 2024/01/10 03:37 PHST- 2023/08/16 00:00 [received] PHST- 2023/09/10 00:00 [revised] PHST- 2023/10/16 00:00 [accepted] PHST- 2024/01/10 06:42 [medline] PHST- 2024/01/10 06:41 [pubmed] PHST- 2024/01/10 03:37 [entrez] PHST- 2023/10/21 00:00 [pmc-release] AID - S2287-8882(23)00056-9 [pii] AID - 10.1016/j.prnil.2023.10.002 [doi] PST - ppublish SO - Prostate Int. 2023 Dec;11(4):239-246. doi: 10.1016/j.prnil.2023.10.002. Epub 2023 Oct 21.